Scroll down

TARGETED ALTERATION OF DNA USING TWO OLIGONUCLEOTIDES

Would you like to explore the possibilities for obtaining a license for this technology? You can contact our licensing team by mail. Would you like to know more about our technologies and licensing possibilities? Visit our webpage about Licensing KeyGene’s proprietary technologies.

Invention

The invention provides for a method for targeted alteration of DNA using two newly designed (donor) oligonucleotides resulting in more efficient Targeted Nucleotide Exchange (TNE) or Oligonucleotide Directed Mutagenesis (ODM).

Benefit

Genome editing technologies are rapidly emerging. Many targeted genome editing technologies require the (co-)transfection of single stranded oligonucleotides designed to direct the repair of a mutation of interest. The patented genome editing technology makes use of two oligonucleotide that are capable of hybridizing to the complementary strands of the DNA. Each of these oligonucleotides has the mismatch located at most two nucleotides of its 3′ end, resulting in efficient TNE.

Vision

Efficient targeted genome editing technologies are important research tools in gene validation and may be used for introduction of new traits in crop germplasm. The more effective genome editing technology of the present invention contributes thereto.

Patent

Click on the link below for an overview of the patent family in the European Patent Register:

WO2012/074386

Please note that the European Patent Register may not be extensive and/or accurate, for which KeyGene is not responsible. Please contact your patent expert for further information.